Top Markets
Coin of the day
OmniAb, Inc. OmniAb, Inc.

OmniAb, Inc.

OABI
Rank in Stocks #11871
OmniAb, Inc. is an American biotechnology firm focused on pioneering... OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Share Price
$4.48
Last synced: 2026-08-28
Market Cap
$649.33M
Change (1 day)
-2.84%
Change (1 year)
179.94%
Country
US
Trade OmniAb, Inc. (OABI)

Category

Earnings for OmniAb, Inc. (OABI)
Earnings in 2026 TTM: 0
According to OmniAb, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for OmniAb, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH